

IMARX THERAPEUTICS INC
Form NT 10-Q
May 17, 2010

OMB APPROVAL
OMB
Number: 3235-0058
Expires: May 31,
2012
Estimated average
burden hours per
response ... 2.50

SEC FILE NUMBER
001-33043

CUSIP NUMBER
45248L308

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING**

(Check one): Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-SAR
Form N-CSR

For Period Ended: March 31, 2010

Transition Report on
Form 10-K

Transition Report on
Form 20-F

Transition Report on
Form 11-K

Transition Report on
Form 10-Q

Transition Report on
Form N-SAR

For the Transition Period
Ended:

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I REGISTRANT INFORMATION

ImaRx Therapeutics, Inc.

Full Name of Registrant

Former Name if Applicable

6860 Lexington Avenue

Address of Principal Executive Office (*Street and Number*)

Los Angeles, CA 90038

City, State and Zip Code

PART II RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Form 10-Q for the period ended March 31, 2010 (the Report) could not be filed within the prescribed time period due to the time spent by the Registrant in pursuing an acquisition during the months of March, April and May 2010. The merger was expected to be completed in March 2010. Should the merger have taken place when expected, the preparation and filing of the Report would have been done by the acquirer. As such, the Registrant's resources were dedicated to the completion of the merger rather than the preparation of the Report during the months of March, April and May 2010 and the Registrant will be unable to file the Report by the prescribed May 17, 2010 due date. The Registrant believes it will be able to file the Report within the 5-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

**Persons who
are to
respond to
the collection
of
information
contained in
this form are
not required
to respond**

**unless the
form displays
a currently
valid OMB
control
number.**

(Attach extra Sheets if Needed)

PART IV OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification

Kevin Ontiveros
(Name)

801
(Area Code)

328-3131
(Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes No

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

ImaRx Therapeutics, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date May 17, 2010

By /s/ Edward A. Sylvan

Edward A. Sylvan, Chief Executive
Officer